← brief for 2026-11-02 · Slowing decline

Recent evidence for reducing cardiometabolic risk in chronic kidney disease.

Paper No results yet Peer reviewed

Key takeaways

This review summarizes recent trials showing that certain drugs protect the heart and kidneys in people with chronic kidney disease. It focuses on SGLT2 inhibitors, along with other newer drug classes. It confirms that these treatments are now standard care. There are no new trial results in this specific article.

Who did this work

Arora N · Ryan E

Source

Paper · PubMed, CKD progression · 2026 Nov 2
https://pubmed.ncbi.nlm.nih.gov/42969252/